-+ 0.00%
-+ 0.00%
-+ 0.00%
Treace Medical Q2 net loss narrows to $15.9 million; revenue falls 4% to $45.4 million
Share
Listen to the news
Treace Medical Q2 net loss narrows to $15.9 million; revenue falls 4% to $45.4 million
  • Treace Medical Concepts posted Q2 2026 revenue of USD 45.4 million, down 4% year over year.
  • GAAP net loss narrowed to USD 15.9 million, or USD 0.24 per share.
  • Non-GAAP adjusted EBITDA loss was USD 3.5 million.
  • Cash, cash equivalents, marketable securities totaled USD 45.6 million at June 30, 2026; year-to-date cash usage fell 57%.
  • Raised 2026 revenue outlook to USD 204 million-USD 212 million; launched limited release of SuperBite, completed first HyperPlate XM case.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070705PRIMZONEFULLFEED9805738) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending